Evidence map›Paper›PMID 28654387›Full record

ArticleMolecular imaging2017

Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential.

Lulu Wang, Amyn A Habib, Akiva Mintz, King C Li, Dawen Zhao

Open access · goldAbstract read
In one paragraph

Article in Molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Integrin Targeting Enhances the Antimelanoma Effect of Annexin V in Mice.International journal of molecular sciences · 2023
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Lulu Wang1 Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Amyn A Habib2 Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Akiva Mintz4 Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
King C Li4 Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Dawen Zhao1 Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Wake Forest University · USDallas VA Medical Center · USThe University of Texas Southwestern Medical Center · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Convertible MRI contrast signaling delivery and release of anti-glioma nano-drugR01CA194578 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ZHAO, DAWEN · 2015 to 2019
$1.8M
Interactions between inflammatory and oncogenic signaling pathways in GBMI01BX002559 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · PI HABIB, AMYN · 2014 to 2021
–
BLRD VA I01 BX002559NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA194578
6 · The paper itself

Abstract

Phosphatidylserine (PS), the most abundant anionic phospholipid in cell membrane, is strictly confined to the inner leaflet in normal cells. However, this PS asymmetry is found disruptive in many tumor vascular endothelial cells. We discuss the underlying mechanisms for PS asymmetry maintenance in normal cells and its loss in tumor cells. The specificity of PS exposure in tumor vasculature but not normal blood vessels may establish it a useful biomarker for cancer molecular imaging. Indeed, utilizing PS-targeting antibodies, multiple imaging probes have been developed and multimodal imaging data have shown their high tumor-selective targeting in various cancers. There is a critical need for improved diagnosis and therapy for brain tumors. We have recently established PS-targeted nanoplatforms, aiming to enhance delivery of imaging contrast agents across the blood-brain barrier to facilitate imaging of brain tumors. Advantages of using the nanodelivery system, in particular, lipid-based nanocarriers, are discussed here. We also describe our recent research interest in developing PS-targeted nanotheranostics for potential image-guided drug delivery to treat brain tumors.

Indexed as

AnimalsBlood-Brain BarrierBrain NeoplasmsCell Line, TumorHumansMolecular ImagingPhosphatidylserinesPhosphatidylserinesblood–brain barrier (BBB)brain tumormolecular imagingnanotheranosticsphosphatidylserine (PS)

Identifiers

PMID28654387
PMCPMC5470144
OpenAlexW2615235831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.